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Abstract
Agents that activate cannabinoid receptor pathways have been tested as treatments for cachexia, nausea or neuropathic
pain in HIV-1/AIDS patients. The cannabinoid receptors (CB1R and CB2R) and the HIV-1 co-receptors, CCR5 and CXCR4, all
signal via Gai-coupled pathways. We hypothesized that drugs targeting cannabinoid receptors modulate chemokine co-
receptor function and regulate HIV-1 infectivity. We found that agonism of CB2R, but not CB1R, reduced infection in primary
CD4+ T cells following cell-free and cell-to-cell transmission of CXCR4-tropic virus. As this change in viral permissiveness was
most pronounced in unstimulated T cells, we investigated the effect of CB2R agonism on to CXCR4-induced signaling
following binding of chemokine or virus to the co-receptor. We found that CB2R agonism decreased CXCR4-activation
mediated G-protein activity and MAPK phosphorylation. Furthermore, CB2R agonism altered the cytoskeletal architecture of
resting CD4+ T cells by decreasing F-actin levels. Our findings suggest that CB2R activation in CD4+ T cells can inhibit actin
reorganization and impair productive infection following cell-free or cell-associated viral acquisition of CXCR4-tropic HIV-1 in
resting cells. Therefore, the clinical use of CB2R agonists in the treatment of AIDS symptoms may also exert beneficial
adjunctive antiviral effects against CXCR4-tropic viruses in late stages of HIV-1 infection.
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Introduction
Cannabinoid agonists are currently under investigation for the
treatment of AIDS-associated cachexia, nausea, and neuropathic
pain [1–3]. One such drug, dronabinol (D
9-THC; MarinolH), has
won Food and Drug Administration (FDA) approval for treatment
of HIV-associated anorexia [4]. Additionally, the prescription of
smoked or ingested cannabis (marijuana) for treatment of AIDS-
related symptoms has been approved in 14 states [5]. Despite the
use of cannabinoids by HIV/AIDS patients, few studies have
investigated the impact of such drugs in regard to viral
pathogenesis or immune regulation. Early studies conducted in
the pre-HAART era suggested a positive correlation between
development of opportunistic infection, progression to AIDS, and
marijuana use [6,7]. Yet recent analysis of HIV/AIDS patients
enrolled a randomized, placebo-controlled clinical trial designed to
study the outcome of cannabinoid administration have indicated
that cannabinoid use does not result in significant immunosup-
pression [1]. Indeed, both smoked marijuana and dronabinol were
reported to increase total CD4+ T cell number [1] and naı ¨ve T
cell number [8] over a 21-day period. A decrease in viral load was
also observed in these patients [1]. Similarly, in SIV infected
rhesus macaques, D
9-THC exposure reduced viral load and CD4+
T cell depletion, significantly increasing animal survival over an 11
month period [9]. Despite these findings, the mechanisms by
which cannabinoid drugs can influence viral replication or
pathogenicity remain unknown.
Cannabinoid agonists activate the CB1R and CB2R cannabi-
noid receptors. Like the HIV chemokine co-receptors CXCR4
and CCR5, CB1R and CB2R are members of the Gai-coupled
family A GPCRs [10]. CB2R is highly expressed on all CD4+ T
cells [11], whereas CB1 expression is found in activated, memory
subsets [12]. CB1 and CB2 have been classified as immunosup-
pressive receptors on CD4+ T cells [13], although antagonism of
CB1R and CB2R does not enhance immune activation and knock-
out mice do not exhibit differences in T cell frequency or increases
in autoimmune pathogenesis [14]. The mechanism(s) by which
cannabinoid agonists can modulate CD4+ T cell function remain
unclear. Activation of CB2R has been shown to inhibit
inflammatory cytokine production in CD4+ T cells [11], which
may account for the decrease in autoimmune pathogenesis
observed in therapeutic trials of cannabinoid agonists in animal
models of multiple sclerosis [14,15]. CB2R may also function as a
chemotactic modulator, as CB2R activation inhibits CXCR4-
induced chemotaxis in transformed lymphocytes [16]. CB2R has
further been shown to regulate lymphocyte egress from the bone
marrow in a role previously attributed largely to CXCR4 [17,18].
These findings suggest that CB2R may play a role in regulating
chemokine receptor signaling, specifically the activity of CXCR4.
Such cross-talk between CB2R and CXCR4 may have implica-
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therapeutic purposes.
Although coreceptor signaling is not essential for HIV-1
infection, several recent studies have suggested that chemokine
receptor signaling enhances infection of resting CD4+ T cells [19–
21]. These cells express CXCR4, but not CCR5, whose expression
is restricted to a small subset of memory CD4+ T cells [22]. In
patients, the emergence of CXCR4-tropic virus usually occurs
after years of infection and correlates with more rapid progression
to AIDS [23,24,25]. Viral conversion to CXCR4-tropism
increases the number of targets available to the virus [26].
Additionally, as HIV-1 can establish latency in resting T cells [27],
a switch to CXCR4-tropism could enhance the establishment of a
latent pools of virus within lymphoid tissues. The increased
number of new targets may explain the rapid decline in CD4+ T
cell numbers and increased viral load in late-stage AIDS patients
with CXCR4-tropic virus [1,24]. The late-stage patients who
frequently harbor CXCR4-tropic virus are also the most likely to
benefit from cannabinoid drug use. It is therefore relevant to study
the potential for cannabinoid signaling to modulate CXCR4
activity and alter the course of HIV infection, Interactions
between GPCRs like CB2R and CXCR4 can cause cross-
desensitization, allosteric modulation, dimerization, changes in
receptor localization, and alteration of physiological function
among GPCR pairings [28]. Given that direct antagonism of
chemokine receptor function can block viral infection [19,29,30],
it is possible that allosteric modulation of CXCR4 through a
GPCR partner may also reduce HIV-1 permissiveness. Indeed,
oligomerization of the chemokine co-receptors including CXCR4
using conformationally specific monoclonal antibodies can inhibit
HIV-1 entry into target cells [31,32]. These experiments
demonstrate signaling-independent modulation of coreceptor
function. Allosteric agents that disrupt HIV-1 infection by
modulating chemokine receptor signaling have not yet been
identified. Should CB2R-induced signaling alter CXCR4 co-
receptor function, this would represent first known example of a
signaling-dependent GPCR interaction leading to viral inhibition.
To test this hypothesis, we examined the effect of cannabinoid
receptor activation on HIV viral transmission and productive
infection in CD4+ T cells using a GFP-expressing, CXCR4-tropic
HIV-1 variant. We found that activation of CB2R on CD4+ T
cells significantly inhibited viral infection in a CB2R -selective and
dose-dependent manner. Viral inhibition was more pronounced in
resting cells that were activated after infection. We investigated
signaling in these cells and found that CB2R agonism significantly
decreased SDF-1a-induced CXCR4 activation. Furthermore,
CB2R agonism altered HIV-induced cytoskeletal rearrangement,
associated with productive HIV infection in resting cells. We found
that CB2R was not sufficient to block viral transfer or fusion, but
did significantly diminish productive viral infection. We conclude
that CB2R is a novel modulator of CXCR4-tropic HIV infection
in CD4+ T cells.
Materials and Methods
Cell culture reagents
Anonymous blood donations were obtained from New York
Blood Center. Cells were cultured as previously reported [33]. The
purified monoclonal antibodies (mAbs) ÆCD2 (OKT3) and ÆCD28
(28.2) were purchased from eBioscience. Phytohemagglutinin
(PHA) and carboxyfluorescein succinimidyl ester (CFSE) was
purchased from Sigma. Recombinant human IL-2 and CXCR4
antagonist AMD3100 were obtained through the AIDS Research
and Reference Reagent Program (NIH). Fluorophore-conjugated
CXCR4 (12GS), CCR5 (T21/8), CD25 (BC96), and CD45RO
were purchased from Biolegend. The CB2 agonists JWH-133,
JWH-150, Ser160, 2-arachidonoylglycerol, and anandamide and
the CB2 antagonist AM630 were purchased from Tocris.
Cell purification and sorting
Total CD4+ T cells were isolated from healthy HIV/hepatitis B
virus-seronegative donors as described previously [33]. For FACS-
sorting, CD4+ T cells were labeled with Live/Dead for viability
(Invitrogen), stained for CD45RO, and sorted with a FACS Aria
(BD Biosciences).
Viral constructs
HIV NL-GI and Gag-iCherry are NL4-3 based CXCR4-tropic
HIV-1 molecular clones that have been described previously [34].
NL-GI expresses green fluorescent protein (GFP) in place of the
viral early gene nef, and nef expression is maintained by insertion
of an internal ribosome entry site (IRES) [35]. Gag-iCherry carries
the GFP variant Cherry inserted internally into Gag between the
MA and CA domains. For CCR5-tropic virus, a variant of NL-GI
expressing the Env gene from the molecular clone JRFL [36] was
used. Virus was produced in HEK293T cells and p24 concentra-
tion was calculated by ELISA prior to use.
Cell-Free Infection Assay
CD4+ T cells were thawed, resuspended in RPMI medium
containing 20 U/ml recombinant IL-2 and stimulated with 1 mg/
ml PHA (Sigma) overnight. Cells were cultured for four days and
reseeded into 96 well flat-bottom plates (Costar) at a density of 10
5
cells/well prior to treatment and infection. Treated cells were
incubated with antagonist or vehicle (DMSO) for one hour at
37uC followed by incubation with agonist or vehicle (DMSO or
0.1% ethanol) for another three hours. Following this treatment,
triplicate cultures were infected with 10 ng/well HIV NL-GI. To
assess HIV infection, fluorescence was assessed at day 4 post-
treatment. Harvested cells were stained for viability and fixed with
4% paraformaldehyde, prior to acquisition on a FACSCalibur
(BD Biosciences) and analysis with FloJo software (TreeStar).
Cell-Associated Infection Assay
HIV-expressing Jurkat donor cells were generated by transfec-
tion using HIV Gag-iCherry, as described previously [34]. To
generate infected CD4+ T cell donors, PHA activated CD4+ T
cells were spinoculated with either HIV NL-GI or for 90 minutes
at 12006g. After 24–48 hours, approximately 10–30% of donor
cells were infected. Donor cells were labeled with 10 mM
CellTracker blue (CMF2HC) fluorescent dye (Invitrogen) and
then co-cultured with unstimulated and antagonist and/or agonist-
treated target cells in a 1:1 ratio for 3 hours at 37uC, as described
previously [33]. Virus transfer was terminated by washing with
PBS and treatment with 0.05% trypsin-EDTA (Invitrogen) for
5 minutes. Cells were stained for viability and for CD45RO prior
to fixation and acquisition on a LSRII (BD Biosciences). Sorted
GFP
2Cherry
2 CD45RO
+ or CD45RO
2 targets were seeded into
96-well plates coated with 2.5 mg/ml anti-CD3 in RPMI media
containing 1 mg/ml anti-CD28 and 20 U/ml rIL-2 for activation.
After 4 days, cells were harvested, fixed, and analyzed for
fluorescence.
Quantitation of Viral Membrane Fusion
Cell-free viral fusion was measured using a method described
previously [37]. BlaM-VPR was a gift from Michael Miller (Merck
Research Laboratories). Viral infections were done with 20 ng of
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analyzed on an LSRII flow cytometer (Becton Dickinson).
Signaling Studies
For GTPcS binding, JWH-133 treated CD4+ T cells were
permeabilized with CHAPS and incubated with increasing
concentrations of SDF-1a. Incorporation of radiolabelled GTPcS
was assayed as described [38]. For kinase phosphorylation and
western blotting, primary CD4+ T cells were treated with
antagonist and/or agonist in serum-free RPMI for a total of
4 hours prior to treatment with SDF-1a (PeproTech) or NL4.3
HIV at various times indicated. Levels of phosphorylated MAP
kinase and total MAP kinase were determined as described [38].
Data Analysis
Data was analyzed with GraphPad Prism using a paired t-test.
Mean and standard error indicate variance between multiple
donors, with n as indicated.
Results
CB2-specific agonists inhibit HIV-1 infection in primary
CD4+ T cells
As activation of the cannabinoid receptor CB2R has been
shown to modify chemokine receptor activity [16] and cannabi-
noid use in HIV-1 infected individuals is associated with
reductions in viral load [1], we hypothesized that CB2R agonism
may alter the course of HIV-1 infection. Using a GFP-expressing
variant of the CXCR4-tropic lab isolate NL4.3 (NL-GI), in which
GFP is expressed in place of the viral gene nef [33], we assayed
HIV-1 infectivity in primary CD4+ T cells pre-treated with CB2R
agonist. Purified, blood-derived CD4+ T cells were stimulated
with low-dose mitogen for four days prior to a three-hour
cannabinoid treatment. To directly test the capacity for CB2R
activation to inhibit viral infection, we pretreated activated CD4+
T cells with a potent and selective CB2R agonist that is
approximately 200-fold selective for CB2R over CB1R
(Ki=3.4 nM) [39] (JWH-133) prior to HIV-1 exposure. Treated
cells were then washed and exposed to virus in suspension (10 ng/
2610
5 cells) for four days. After this time, the frequency of GFP+
infected cells was measured and the frequency of inhibition, as
compared to control (DMSO treated) infection, was calculated.
When cells were treated with 100 nM of JWH-133 prior to viral
exposure, we observed an approximately 40% reduction in HIV-1
infected cells after four days (Figure 1A–B). This inhibition was
significantly reduced when CB2R activity was selectively blocked
using the antagonist AM630, indicating that the antiviral activity
of JWH-133 is indeed CB2R-specific (Figure 1A–B). JWH-133-
mediated blockade of HIV-1 infectivity was dose-dependent, with
an EC50 of 7.5960.1 nM and a plateau of efficacy at
approximately 50% inhibition (Figure 1B). Further, the action
of this drug was CXCR4-specific, as JWH-133 treatment was not
sufficient to inhibit infection with an isogenic virus that carried a
CCR5-tropic Env from molecular clone JRFL (Figure 1C).
Therefore, CB2 activation reduces CXCR4-tropic HIV-1 infection
in primary CD4+ T cells in a dose-dependent and receptor-
specific fashion.
To further confirm this novel role for CB2R, we tested other
CB2R-selective agonists (JWH-015 and Ser016) to see if treatment
was sufficient to reduce viral infectivity. Both of the highly specific
CB2R agonists we tested proved to be antiviral at concentrations of
1 mM; these were JWH-015 (35.9611.96% inhibition) and Ser016
(30.7613.72%inhibition)(mean6SEM,n=8donors)(Figure1D).
Treatment with 1 mM of the pan-cannabinoid agonist Hu210 also
significantly reduced HIV-1 infection, although to a lesser extent
than with CB2R-selective agonists (23.967.45%, mean6SEM,
n=8 donors) (Figure 1D). The reduction in infection efficiency
observed with Hu210 was CB2R-specific and was not observed
when cells were pretreated with the CB2R-selective antagonist
AM630 (Figure 1D). Consistent with these findings, 1 mM
pretreatment with the CB1R selective agonist arachidonyl-29-
chloroethylamide (ACEA)didnot significantlyreduceviralinfection
(4.7663.13%, mean6SEM, n=5 donors) (Figure 1D). These
results indicate that CB2R-selectiveagonists, butnot CB1R-selective
agonists, can inhibit HIV-1 permissiveness.
Given that the pan-cannabinoid agonist Hu210 possessed
antiviral activity, we predicted that naturally occurring endoge-
nous ligands of the cannabinoid receptors, the endocannabinoids
2-arachidonoylglycerol (2-AG) and anandamide (AEA) could
reduce infectivity via CB2R activation. We found that pretreat-
ment with either 2-AG or AEA significantly inhibited HIV-1
infection in a dose-dependent and CB2-specific manner
(Figure 1E–F). AEA, which is reported to have higher affinity
for CB2R than 2-AG (Ki=371 nM versus 1400 nM, respectively)
[40], proved to be a more potent inhibitor of virus, with an EC50
of 8.5960.09 nM, as compared to 1.8260.25 mM for 2-AG. The
antiviral activity of both of these endocannabinoid agents was
abrogated by treatment with 1 mM of the CB2R-selective
antagonist AM630. These data demonstrate that, like synthetic
cannabinoid agonists, the endocannabinoids can activate CB2Rt o
inhibit HIV-1 infectivity in CD4+ T cells.
CB2 activation does not alter CXCR4 expression or T cell
activation
We next sought to determine the mechanism of HIV-1
inhibition via CB2R. Previous reports have indicated that
cannabinoid treatment of immune cells can lead to changes in
cell surface chemokine receptor expression [41], loss of prolifer-
ative capacity [11], and reduction in effector function [42,43]. We
examined whether CB2R activation in our infection model led to
either a reduction in co-receptor expression or in host fitness,
rendering the cells incapable of harboring productive viral
infection. To test this possibility, we treated CD4+ T cells with
the CB2 agonist JWH-133 with a concentration of drug sufficient
to inhibit viral infection (100 nM). We found that this treatment
did not lead to significant reduction of CXCR4 cell surface
expression (Figure 2A–B) or total CXCR4 protein expression
(data not shown).
Likewise, pretreatment with up to 1 mM of JWH-133 prior to
TCR-mediated activation did not reduce T cell activation, as
measured by an increase in CD25 expression, or proliferation, as
indicated by CFSE dilution after stimulation with anti-CD3 and
anti-CD28 antibodies (Figure 2C–E). Concentrations of JWH-
133 ranging from 1 mM and below did not lead to a change in
cell viability as compared to DMSO treated controls (data not
shown). Higher concentrations of JWH-133 or Hu210 (10 mM
and above) did lead to apoptosis and cell death, consistent with
published observations [11]. Our findings indicate that low doses
of the CB2R agonist JWH-133 are sufficient to inhibit viral
infection without significant disruption of CD4+ Tc e l lc o -
receptor expression, CD4 expression, CD25 upregulation, or
proliferation. Further, CB2R agonism did not alter the ability of
the CD4+ T cell to support viral infection, as JWH-133 treated
cells are readily infected by the CCR5-tropic JRFL virus
(Figure 1C). Taken together, these data suggest that CB2R
activation is altering a pathway specifically required for CXCR4-
tropic infection.
CB2 Agonism Attenuates HIV-1 in CD4 T Cells
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in unstimulated CD4+ T cells
Despite intense study, the importance of GPCR-mediated
signaling during CXCR4-tropic HIV-1 infection remains unclear.
Recently, several lines of study have demonstrated a role for
chemokine receptor signaling in resting CD4+ T cells [44].
Activation of Gai-coupled chemokine receptors enhances infec-
tivity in resting CD4+ T cells that are stimulated with gp120 or
chemokine agonist after exposure to HIV-1 [19,20]. Conversely,
inhibition of GPCR function by pertussis toxin inhibits viral
infection [19]. This has been described as a model for latent
infection in resting cells [19,45]. We tested to see if the CB2 agonist
JWH-133 differentially inhibited HIV-1 infection in resting versus
activated cells.
Cells were activated with mitogen four days before (activated)
(Figure 3A) or four days after (resting) (Figure 3B) treatment
with 100 nM JWH-133 or 1 mM pertussis toxin and exposure to
virus. We found that JWH-133 and pertussis toxin partially
Figure 1. Cannabinoid inhibition of CXCR4-tropic HIV-1 infection is dose-dependent and CB2-selective. (A) HIV-1 (GFP) expression 4
days post-infection in primary CD4+ T cells pretreated with 100 nM of the CB2-specific agonist JWH-133 and/or the CB2-specific antagonist AM630 in
a representative donor. HIV expression (GFP; FL1) is shown on the x-axis, and an empty channel (FL3) is shown on the y-axis. (B) Dose-dependent
inhibition of viral infection by JWH-133 in primary CD4+ T cells is blocked by 100 nM of the CB2 antagonist AM630 (mean6SEM; n=7 donors;
**p=0.0032, *p,0.03). (C) Inhibition of CXCR4-tropic (NL4-3) but not CCR5-tropic (JRFL) HIV-1 after 4 days in primary CD4+ T cells pretreated with
100 nM of JWH-133 (mean6SEM; n=5 donors). (D) Inhibition of viral infection in cells pretreated with the CXCR4 antagonist AMD3100 (which is
predicted to block viral binding [57]), or 1 mM of cannabinoid agonists ACEA, Hu210, JWH-133, JWH-015 and Ser016 with or without pretreatment
with the CB1 antagonist AM251 or the CB2 antagonist AM630. (E–F) Dose-dependent inhibition of NL-G1 infection in primary CD4+ T cells pretreated
with (F) 2-arachidonoylglycerol (2-AG) or (G) anandamide (AEA) is blocked by 1ı `M of the CB2 antagonist AM630 (mean6SEM; n=5 donors; *p,0.03).
doi:10.1371/journal.pone.0033961.g001
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(Figure 3). Consistent with previous reports [19], inhibition by
pertussis toxin was augmented in resting cultures as compared to
activated cultures (59.38629.5% versus 41.16620.6%, respec-
tively, *p,0.05) (mean6SEM, n=4). Similarly, we found that the
efficacy of JWH-133–mediated viral inhibition was significantly
increased in resting, as compared to activated, cultures (63.346
31.7% versus 36.31618.2%, respectively, *p,0.05 (mean6SEM,
n=4) (Figure 3C). These data are consistent with the premise
that alteration of GPCR signaling predominantly alters viral
infection in resting cells.
CB2R agonism inhibits SDF-1a mediated CXCR4 signaling
Our data suggested that CB2R activation specifically inhibited
CXCR4-tropic virus and that this effect was greatest in resting
cells. Given a previous report, which indicated that CXCR4
signaling enhances HIV-1 infection in resting cells [19], we chose
to investigate the functional consequence of CB2R stimulation on
CXCR4-mediated signaling. To assay for CXCR4 activity, we
first measured changes in a G protein activity in CD4+ T cells
activated by the cytokine SDF-1a (CXCL12). SDF-1a treatment
led to a robust, dose-dependent increase in [
35S]GTPcS binding in
CD4+ T cells (Figure 4A). Pretreatment with 100 nM JWH-133
significantly decreased this effect at higher doses (16.768.37%,
**p=0.0034) (mean6SEM, n=4 donors) (Figure 4B). In
contrast, pretreatment with SDF-1a did not inhibit JWH-133
induced [
35S]GTPcS binding at any concentration tested
(Figure 4C). CB2 agonism therefore decreases G-protein
activation in response to the CXCR4 agonist SDF-1a.
The CB2R-induced inhibition of CXCR4 signaling was also
indicated by a decrease in phosphorylation of downstream kinases
following SDF-1a treatment (Figure 5). We assayed SDF-1a-
induced Akt and p32/44 MAP kinase (ERK 1/2) phosphorylation
in CD4+ T cells following treatment with or without CB2R agonist
JWH-133. SDF-1a-mediated phosphorylation of both Akt
(Figure 5A–B) and ERK 1/2 (Figure 5C–D) was significantly
inhibited by pretreatment with JWH-133. These results suggest
that the activation of CB2R is sufficient to inhibit downstream
CXCR4-mediated signaling pathways.
The CB2R agonist JWH-133 decreases F-actin in CD4+ T
cells
Down-regulation of CXCR4 signaling with pertussis toxin has
been shown to decrease actin dynamics, disrupting the remodeling
of the cortical actin barrier required for HIV-1 infection [19].
Given the capacity for CB2R agonism to inhibit upstream
CXCR4-mediated signaling events, we hypothesized that CB2R
could suppress CXCR4-induced actin polymerization. To test for
this possibility, we assayed the ability of JWH-133 to inhibit SDF-
1a mediated actin polymerization, as visualized by phalloidin
binding. While a significant difference in the rate of SDF-1a
induced F-actin accumulation was not detected (data not shown),
we did find that JWH-133-treatment led to a significant decrease
in phalloidin binding as compared to untreated control cells
(Figure 6A–B) (at time 0, 46.2617.46 versus 64.36624.34 MFI,
respectively; after 30 minutes of SDF-1a treatment, 23.36611.68
versus 31.3615.65 MFI, respectively) (mean6SEM, n=7,
**p=0.0021, *p=0.04). Although CB2R agonism was found to
disrupt SDF-1a induced G protein binding and signaling
(Figure 4 and 5), this decrease did not translate into acute
disruption of the rate of actin polymerization following SDF-1a
treatment. Therefore it is possible that CB2R exerts its effect at the
level of F-actin formation as treatment with JWH-133 reduces the
level of F-actin in the steady state.
During HIV-1 infection, the virus itself acts as an agonist to
stimulate CXCR4 and induce actin remodeling in resting cells
[46,47]. We tested to see whether changes in actin reorganization
caused by viral binding were altered by CB2R agonist pretreat-
ment. To do so, we pretreated CD4+ T cells with JWH-133,
incubated these cells with HIV-1 viral particles, and then
measured changes in phalloidin binding to F-actin over time.
We found that HIV-1 induced transient upregulation in phalloidin
binding activity peaking at approximately 1 minute after addition
in both control and JWH-133 treated cells (Figure 6C). Like with
SDF-1a treatment, the rate of increase in phalloidin binding was
not significantly altered in CB2R agonist pretreated cells.
Consistent with our previous observations, we found that that
basal phalloidin binding was significantly reduced in JWH-133
treated cells. The reduction in F-actin formation in JWH-133
treated cells was consistent over time despite the transient
upregulation of phalloidin stain induced by virus (Figure 6C).
Figure 2. CB2 agonism at concentrations sufficient to inhibit
HIV-1 infection does not significantly alter cell-surface CXCR4
expression or inhibit cellular proliferation in primary CD4+ T
cells. (A–B) Cell surface expression of CXCR4 in CD4+ T cells pretreated
with either DMSO or 100 nM of JWH-133 (A) in a representative donor
and (B) in multiple donors (mean6SEM; n=4 donors). (C–E) Prolifer-
ation, as indicated by CFSE dilution; and activation, as measured by
CD25 expression; in CD4+ T cells, stimulated with cross-linking anti-CD3
and anti-CD28 mAb, 4 days after pretreatment with 100 nM of JWH-133
(C) in a representative donor and (D–E) in multiple donors (mean6SEM;
n=5 donors).
doi:10.1371/journal.pone.0033961.g002
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induced by CB2R agonism results in the reduction of total F-actin
over time, despite addition of CXCR4 agonists such as SDF-1a or
HIV-1 viral particles. The rate of actin polymerization remained
constant after acute CXCR4 activation, but the total amount of F-
actin induced was significantly lower in cells pretreated with CB2R
agonist. Indeed, the amount of F-actin induced by wild type virus
in JWH-133 pretreated cells was similar to that induced by Env-
null viral particles in control treated cells (at 1 minute, 107.5653.7
versus 95.9647.9) (mean6SEM, n=4) (Figure 6D). Therefore,
JWH-133 treatment reduces F-actin concentration to background
levels, that is, the same level as non-specific induction of actin by
Env-null virus. This basal reduction in actin polymerization via
CB2R may reduce actin rearrangement sufficiently to block viral
infection.
CB2R agonism decreases HIV-induced cofilin activation
HIV-triggered actin rearrangement is regulated in part by the
severing protein cofilin, which dissociates and facilitates depoly-
merization of actin filaments thereby promoting actin dynamics
[45]. In the inactive state, cofilin is phosphorylated; agonism of
Gai-coupled chemokine receptors initiates cofilin de-phosphory-
lation and activity [20]. Induction of cofilin de-phosphorylation
increases HIV infection [19], we therefore hypothesized that
JWH-133 treatment, which decreases HIV infection, would lead to
increased cofilin phosphorylation. To identify changes in cofilin
regulation, we measured phosphorylated cofilin (p-cofilin) expres-
sion in CD4+ T cells pretreated with JWH-133 and exposed to
HIV. We detected a significant increase of p-cofilin over time in
JWH-133 treated cells, as compared to control treated cells
(216.426124.95 versus 146.83684.77, respectively, p-cofilin
Figure 3. Inhibition of HIV-1 infection by CB2 activation is enhanced in CD4+ T cells infected prior to activation. (A–C) Infection, as
measured by GFP expression, in primary CD4+ T cells activated with mitogen (A) for 4 days prior or (B) 4 days after treatment with pertussis toxin or
100 nM of the CB2 agonist JWH-133 (A, B) in a representative donor and (C) in multiple donors (mean6SEM; n=4 donors; *p,0.05).
doi:10.1371/journal.pone.0033961.g003
Figure 4. CB2 agonism inhibits SDF-1a ´ mediated G-protein coupling to CXCR4. (A–B) GTPa ˜S binding following addition of the CXCR4
agonist SDF-1a ´ to permeabilized primary CD4+ T cells pretreated with either DMSO or 100 nM of the CB2 agonist JWH-133 (A) in a representative
donor and (B) in multiple donors (mean6SEM; n=4 donors; **p=0.0034, *p,0.02). (C–D) GTPa ˜S binding following addition of the CB2 agonist JWH-
133 to permeabilized CD4+ T cells pretreated with either DMSO or 100 nM of the CXCR4 agonist SDF-1a ´ (C) in a representative donor and (D) in
multiple donors (mean6SEM; n=4 donors).
doi:10.1371/journal.pone.0033961.g004
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*p,0.05) (Figure 6E–F). This data suggests that CB2R agonism
not only blocks HIV-induced cofilin de-phosphorylation, but also
enhances p-cofilin. Indeed, CB2R-induced p-cofilin was also
observed in cells exposed to a control, VSV-envelope pseudotyped
virus (183.11691.56 JWH-133 versus 138.32669.16 control, p-
cofilin density normalized to actin at 120 minutes) (mean6SEM,
n=4, *p,0.05) (data not shown). We did not observe changes in
total cofilin levels in cells treated with HIV and JWH-133
(Figure 6G). Taken together, our data indicate that CB2R agonist
pretreatment leads to accumulation of p-cofilin as well as the
inhibition of cofilin dephosphorylation, i.e. activation in the
presence of HIV; findings consistent with a known requirement for
cofilin activation in HIV infection [19]. The increase of inactive
cofilin in JHW-133 treated cells is a likely mechanism for the
reduction of actin dynamism and subsequent inhibition of viral
infection in these cells.
CB2R agonism inhibits productive infection, but not viral
fusion
Alteration of actin dynamics has been shown to inhibit
productive viral infection but not viral binding or fusion [46].
To confirm that CB2R-mediated changes in the actin cytoskeleton
did not inhibit viral fusion, we assessed levels of fusion using a b-
lactamase (BlaM)-Vpr fusion assay [37]. NL4.3 virions that
incorporated BlaM-VPR were used to infect JWH-133 and
control treated cells loaded with the b-lactamase substrate
CCF2-AM. Upon viral membrane fusion, BlaM-Vpr is released
into the cytoplasm where it is able to cleave CCF2-AM. Infection
of primary, resting CD4+ T cells induced fusion in approximately
4% of cells (Figure 7A). We found that blockade of HIV binding
with the CXCR4 antagonist AMD3100 significantly reduced viral
fusion and CCF2-AM cleavage, but pretreatment with JWH-133
had no effect (Figure 7 A–B). This data indicates that CB2R
antagonism of CXCR4 function does not block the early stages of
viral infection binding and fusion.
CB2R agonism inhibits cell-associated viral infection, but
not transfer
Our findings suggest that CB2R agonism strongly inhibits post-
fusion events during viral infection in resting cells exposed to cell-
free virus. Given these observations, we wanted to determine the
capacity for CB2R agonism to block viral transmission and
infectivity in a cell-associated model of infection. Cell-associated
viral infection is hundreds to thousands-fold more efficient than
cell-free infection [33,48]. During cell-associated transmission, a
synaptic structure, called the viral synapse, is formed between the
infected (‘‘donor’’) and non-infected (‘‘target’’) cell [49]. Significant
actin rearrangements accompany formation of the virological
synapse [50], and these actin structures have been hypothesized to
regulate viral penetration into the target cell [51]. Unlike cell-free
viral infection, transfer of virus between cells is co-receptor
independent; blockade of viral binding to CXCR4 with a selective
antagonist, AMD3100, does not inhibit passage of virus [34].
Once virus is captured within a target cell, however, co-receptor
binding is still required for viral fusion. We hypothesized that
CB2R agonism, like the CXCR4 antagonist AMD3100, would not
inhibit viral transfer, but would block productive infection.
To assay the impact of CB2R agonism on cell-associated viral
transfer, we used a CXCR4-tropic NL4-3-based reporter virus
called HIV Gag-iGFP, which carries an interdomain insertion of
green fluorescent protein (GFP) in the core structural protein Gag
[52]. Each mature viral particle contains ,5000 GFP mole-
cules
(53), so viral transmission can be measured with high
sensitivity [34]. We pretreated CD4+ T cell targets with
AMD3100 or JWH-133, and then co-cultured these cells with
dye-labeled Jurkat donors infected with the HIV Gag-iCherry
reporter virus. After three hours of co-culture, we assessed viral
transmission to the target population (Figure 7C–D). As
previously reported, we found no difference in expression of the
HIV Gag-iCherry reporter virus in CD4+ T cells pretreated with
AMD3100 as compared to control treated cells. Likewise,
pretreatment with the CB2 agonist JWH-133 did not impair viral
transfer into target cells (Figure 7D). Within this T cell
population, transmission to memory (CD45RO+) CD4+ T cells
was approximately 50% more efficient than transfer into naive
(CD45RO-) cells. Transfer to both T cell subsets was as efficient in
AMD3100 and JWH-133 cells as control treated cells. These
findings confirm that CB2R-mediated inhibition of CXCR4
function does not impair cell-associated HIV-1 transfer to either
naive or memory T cells.
We next sought to determine whether CB2R agonist pretreat-
ment blocked productive infection following cell-to-cell transfer of
virus. We pretreated cells with either AMD3100 or JWH-133 and
then conducted a 3-hour transfer experiment using dye-labeled
donor CD4+ T cells infected with the NL-GI virus, the same as
Figure 5. CB2 agonism inhibits acute SDF-1a ´ mediated
s i g n a l i n gi np r i m a r yC D 4 + Tc e l l s .(A–B) SDF-1a ´ induced
phosphorylation of Akt and (C–D) p42/44 MAP kinase is downregulated
in CD4+ T cells pretreated with 100 nM of the CB2 agonist JWH-133. (A,
C) Representative western blots of phospho-kinase expression follow-
ing SDF-1a ´ treatment for 0, 0.5, 1, 5, 15 or 30 minutes. (B, D)
Quantification of kinase phosphorylation in multiple donors (mean6-
SEM; n=3 donors; *p,0.05) taken over basal, defined as signal at time
0.
doi:10.1371/journal.pone.0033961.g005
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We then sorted the naı ¨ve (CD45RO-) targets from the memory
(CD45RO+) target T cell population and activated both subsets to
initiate viral replication. We found that in both naive and memory
T cells, both AMD3100 and JWH-133 pretreatment inhibited
productive viral infection (Figure 7E–G). This inhibition was
significant in the memory population, with CB2R agonist
pretreatment resulting in an approximately 50% decrease in
infected cells after four days of culture (4.0262.0% versus
7.4763.7% control) (mean6SEM, n=4, *p,0.05) (Figure 7F).
Although naive cells overall exhibited productive infection at a
much lower frequency than memory cells, JWH-133 pretreatment
reduced the number of infected cells (0.0260.01% versus
0.260.1%) (mean6SEM, n=4) (Figure 7E). These results
indicate that CB2R agonism blocks productive viral infection after
cell-associated viral exposure, just as it does with cell-free virus.
The capacity for CB2R agonism to block infection following viral
transfer is consistent with our finding that CB2R-mediated
inhibition infection occurs after binding, and indeed fusion, in a
cell-free system (Figure 7A–B). Taken together, these results are
consistent with the idea that actin rearrangements inhibited by
CB2R, while not required for cell-associated viral transfer, are
required for productive viral infection following cell-associated
transfer.
Discussion
Human immunodeficiency virus type 1, (HIV-1) infection in T
cells requires viral binding to two receptors, CD4+ and a
chemokine co-receptor, either CXCR4 or CCR5 [54]. These
co-receptors are members of the highly conserved family A of G-
protein coupled receptors (GPCRs). Absence of co-receptors, or
blockade of HIV-1 binding to one of these co-receptors, are both
sufficient to abrogate de novo viral infection in a target cell [55].
Similarly, manipulation of these GPCRs with pharmacological
ligands that alter co-receptor recycling [56], binding pocket
occupancy [57], or co-receptor activity [19] also inhibit viral
replication.
Here, we report that cannabinoid activation of CB2R inhibits
CXCR4-tropic HIV infection by altering CD4+ T cell actin
dynamics. We find that selective CB2 activation blocks both cell-
free and cell-associated viral infection, reducing the frequency of
infected cells by 30-60% (Figures 1,7). This inhibition is
pronounced in resting cells, which are a target of CXCR4-tropic
HIV [44]. Additionally, this inhibition is mediated post-transfer
during cell-to-cell infection and post-fusion in the target cell
following infection with cell-free virus (Figure 7). We further
investigated the mechanism by which CB2R agonism altered HIV
permissiveness. Our findings demonstrate that CB2R activation at
concentrations sufficient to inhibit virus does not alter CXCR4
levels of surface expression, but does significantly reduce CXCR4-
mediated G-protein binding and downstream signaling (Figure 4
and 5). This inhibition of CXCR4 signaling is accompanied by a
loss in F-actin accumulation (Figure 6), which may prevent the
cortical actin rearrangements required for reverse transcription
and migration of the viral preintegration complex to the nucleus
[58]. Taken together, our results suggest that CB2 cross-regulates
CXCR4 and that this inhibitory cross-talk is sufficient to decrease
viral infection.
Although we here identify cross-talk between the CB2R and
CXCR4 receptors and downstream impairment of actin dynam-
ics, the possibility remains that CB2R activation results in
induction of unknown anti-viral host factors. Arguing against the
possible induction of unknown anti-viral factors, CB2R agonism
did not block HIV infection by virus bearing the CCR5-tropic
JRFL envelope (Figure 1C). The inability of CB2 to inhibit
CCR5-tropic virus suggests that CB2-mediated alterations to the
target cell are negligible in the predominantly memory CCR5+
CD4+ T cell subset. This effect is unlikely to be specific to memory
cells as a whole, as CB2R treatment efficiently blocked productive
Figure 6. Alteration of actin organization in primary CD4+ T cells pretreated with CB2 agonist. (A–B) Total F-actin, as measured by
phalloidin binding, following 3 hours of pretreatment with 100 nM of the CB2 agonist JWH-133 in (A) a representative donor and (B) multiple donors
(mean6SEM; n=7 donors; **p=0.0021). (C) Normalized change in phalloidin binding as a result of HIV-1-mediated CXCR4 activation in CD4+ T cells
pretreated with DMSO or JWH-133 (mean6SEM; n=4 donors; *p,0.05). (D) Mean phalloidin binding in DMSO or JWH-133 pretreated CD4+ T cells
treated for 1 minute with wild type (WT) or Env null (A ¨Env) HIV-1 (mean6SEM; n=4 donors; *p,0.05). (D–E) Cofilin phosphorylation following HIV-1
or VSV-pseudotyped viral exposure in CD4+ T cells pretreated with DMSO or JWH-133 in (D) a representative donor and (E) in multiple donors
(mean6SEM; n=3 donors; *p,0.05). (F) Cofilin phosphorylation and total cofilin following HIV-1 exposure in CD4+ T cells treated with JWH-133.
doi:10.1371/journal.pone.0033961.g006
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with cell-associated X4-tropic HIV-1 (Figure 7F–G). Rather,
these findings may indicate that infection with CCR5-tropic virus
is less dependent on chemokine-receptor mediated signaling and de
novo cytoskeletal rearrangement for productive infection.
The CB2R may be considered as an adjunct therapeutic target
for inhibition of CXCR4-tropic viral spread to resting T cell
populations in patients with AIDS. A particularly compelling
therapeutic rationale for the evaluation of antiviral affects of CB2R
agonists may be to address severe symptoms of cachexia or
neuropathic pain which may also present in patients with AIDS,
without the adverse neurological or behavioral side effects
associated with CB1R agonism [59]. Although the effect of
CB2R agonists on HIV infection is moderate, an accumulated
effect in patients treated daily for pain could explain positive
effects on viral load over time. We find that CB2R agonist
pretreatment of resting cells inhibits viral spread in a receptor-
selective manner in resting cells and does broadly inhibit T cell
activation (Figure 2). Although previous studies have indicated
that pan-cannabinoid agonists can possess an immunosuppressive
function in vitro [11] and in vivo [42,43], ablation of CB2R in mice
was not found to increase T cell number, proliferation, or
apoptosis in the periphery [14]. Immunosuppression by CB2R
may be attributed in part to drug toxicity at high concentrations of
cannabinoid agonist. Indeed, the use of cannabinoid drugs in
patients with HIV is associated with an increase, rather than a
decrease, in CD4+ T cell number [1] and has been shown to
reduce viral load in SIV infected rhesus macaques [9]. It is possible
that novel CB2R-specific agonists and allosteric modulators that
exert potent anti-viral activity without inducing immunosuppres-
Figure 7. CB2 agonism inhibits productive infection of CXCR4-tropic HIV-1, but not cell-associated transfer or viral fusion. (A–B) Viral
fusion, as indicated by a ˆ-lactamase cleavage, in primary CD4+ T cells pretreated with either JWH-133 or AMD3100 in (A) a representative donor and
(B) in multiple donors (mean6SEM; n=4 donors). (C) Transfer of HIV (Gag-iCherry) from infected Jurkat donors to memory (CD45RO+) or naive
(CD45RO-) primary CD4+ T cells pretreated with 100 nM of the CB2 agonist JWH-133 or the CXCR4 antagonist AMD3100, in a representative donor.
(D) Quantification of viral HIV (Gag-iCherry) transfer from Jurkat donors after 3 hours in CD45RO+ and CD45RO- cells pretreated with JWH-133 or
AMD3100 (mean6SEM; n=4 donors). (E–G) Productive infection following HIV transfer from primary CD4+ donors infected with HIV (GFP). Pretreated
CD4+ targets were cocultured with infected CD4+ donor for 3 hours, sorted by CD45RO expression, and then activated. HIV (GFP) expression is
shown in (E) CD45RO- naive or (F) CD45RO+ memory CD4+ T cells after 4 days of activation with IL-2 and anti-CD3/CD28 or anti-CD3 alone,
respectively. (G) Quantification of productive infection post-activation in sorted CD45RO- or CD45RO+ CD4+ T cells pretreated with JWH-133 or
AMD3100 (mean6SEM; n=4 donors; **p=0.0099; *p,0.05).
doi:10.1371/journal.pone.0033961.g007
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neuroendocrine regulators that selectively modulate immune
function may result in the discovery of new anti-viral drugs that
can also mitigate AIDS-associated symptoms.
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